Laura Soler, MD
Internal Medicine · Portland, TXNPI 1619165123
Payments from drug & device makers
Across 331 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$605
- AstraZeneca$510
- Lilly USA, LLC$465
- AbbVie$365
- Pfizer$318
- GSK$279
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,85499%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $605 |
| AstraZeneca | 28 | $510 |
| Lilly USA, LLC | 43 | $465 |
| AbbVie(2 entities) | 24 | $365 |
| Pfizer | 28 | $318 |
| GSK | 18 | $279 |
| Amgen | 21 | $268 |
| Sanofi-aventis U.S. LLC | 19 | $257 |
| Johnson & Johnson | 17 | $253 |
| Boehringer Ingelheim | 11 | $205 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $166 |
| Mylan Specialty L.p. | 4 | $107 |
| Merck | 7 | $105 |
| Ardelyx, Inc. | 3 | $86 |
| Novartis | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $79 |
| Sumitomo Pharma America, Inc. | 4 | $78 |
| Exact Sciences | 4 | $75 |
| Bayer | 4 | $75 |
| Abbott | 3 | $61 |
| Phathom Pharmaceuticals, Inc. | 3 | $60 |
| Teva Pharmaceuticals USA, Inc. | 5 | $58 |
| Eisai Inc. | 3 | $52 |
| Shire North American Group Inc | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $40 |
| Genentech USA, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $28 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| CSL Behring | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $11 |
How this compares
$4,895 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 270 | $317,587 |
| OzempicSemaglutide | 73 | $83,363 |
| EliquisApixaban | 103 | $78,550 |
| MyrbetriqMirabegron | 62 | $44,586 |
| RybelsusSemaglutide | 34 | $42,419 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $41,957 |
| XareltoRivaroxaban | 49 | $41,256 |
| GemtesaVibegron | 51 | $35,454 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $32,635 |
| LinzessLinaclotide | 37 | $31,889 |
| FarxigaDapagliflozin Propanediol | 29 | $26,732 |
| SymbicortBudesonide/Formoterol Fumarate | 85 | $26,314 |
| ProliaDenosumab | 15 | $25,239 |
| JardianceEmpagliflozin | 27 | $23,334 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $20,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $465 | $337,877286 claims |
| Novo NordiskOzempic, Rybelsus | $605 | $125,782107 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $510 | $95,003154 claims |
| PfizerEliquis | $318 | $78,550103 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Synjardy | $205 | $60,10981 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $44,58662 claims |
| Johnson & JohnsonXarelto | $253 | $41,25649 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $78 | $35,45451 claims |
| AbbVieLinzess, Lumigan | $365 | $35,12650 claims |
| MerckJanumet, Belsomra | $105 | $25,93233 claims |
| AmgenProlia | $268 | $25,23915 claims |
| GSKTrelegy Ellipta | $279 | $16,46618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Portland
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.